Introduction: Ampyra (Am) is a potassium channel blocker used in the treatment of patients with spinal cord injury (SCI) or multiple sclerosis (MS). There is evidence that Am is a drug with therapeutic value in enhancing neurological function and neurotransmission in preserved axons. It has been approved by U.S. Food and Drug Administration (FDA) for the treatment of MS on, 2010 [1]. It has been suggested that the concentration of Am in biological fluids should be monitored in clinical trials involving the use of Am because of its high toxicity [2]. Experimentals: This work has presented a novel strategy to carry out indirect and sensitive determination of ampyra in complex matrices based on the interaction of Am with UA. For this propose Graphene oxide nanoribbon (GONR) was synthesized according to the method reported by Wei-Hung Chiang and coworkers [3]. Then FePt nanoparticles was synthesized at the GONRs. FePtGNR nanocomposites was obtained and added to uric acid (UA) solution. Obtained UA@FePtGNR nanocomposite was dropped on the screen printed carbon electrode and related DPV signal was recorded. Results and Discussion: Structure of synthesized nanocomposite was characterized by different techniques including Fourier transform infrared (FT-IR), X-ray powder diffraction (XRD), Transmission electron microscopy (TEM). Obtained experimental results indicated that in present of Am, oxidation peak current of uric acid was decreased. Therefor variation in oxidation current (ΔI) that arises from Am, can be applied as indicating signal for the indirect electrochemical determination of ampyra. Analytical performance of the sensor was investigation by determination of different concentration of ampyra by using differential pulse voltammetry (DPV) method under optimized condition. The relationship between ΔI and Am concentration was linear in the range 0.08 to 9 µM (see fig. 1). The limit of detection for the proposed sensor was estimated as 0.0279 µM (3δblank/m)
